243 related articles for article (PubMed ID: 17106785)
1. Effectiveness of bisphosphonates on nonvertebral and hip fractures in the first year of therapy: the risedronate and alendronate (REAL) cohort study.
Silverman SL; Watts NB; Delmas PD; Lange JL; Lindsay R
Osteoporos Int; 2007 Jan; 18(1):25-34. PubMed ID: 17106785
[TBL] [Abstract][Full Text] [Related]
2. Effectiveness of risedronate and alendronate on nonvertebral fractures: an observational study through 2 years of therapy.
Lindsay R; Watts NB; Lange JL; Delmas PD; Silverman SL
Osteoporos Int; 2013 Aug; 24(8):2345-52. PubMed ID: 23612793
[TBL] [Abstract][Full Text] [Related]
3. Longitudinal change in clinical fracture incidence after initiation of bisphosphonates.
Abelson A; Ringe JD; Gold DT; Lange JL; Thomas T
Osteoporos Int; 2010 Jun; 21(6):1021-9. PubMed ID: 19722103
[TBL] [Abstract][Full Text] [Related]
4. Relative effectiveness of osteoporosis drugs for preventing nonvertebral fracture.
Cadarette SM; Katz JN; Brookhart MA; Stürmer T; Stedman MR; Solomon DH
Ann Intern Med; 2008 May; 148(9):637-46. PubMed ID: 18458276
[TBL] [Abstract][Full Text] [Related]
5. Oral bisphosphonates reduce the risk of clinical fractures in glucocorticoid-induced osteoporosis in clinical practice.
Thomas T; Horlait S; Ringe JD; Abelson A; Gold DT; Atlan P; Lange JL
Osteoporos Int; 2013 Jan; 24(1):263-9. PubMed ID: 22736069
[TBL] [Abstract][Full Text] [Related]
6. Health-economic comparison of three recommended drugs for the treatment of osteoporosis.
Brecht JG; Kruse HP; Möhrke W; Oestreich A; Huppertz E
Int J Clin Pharmacol Res; 2004; 24(1):1-10. PubMed ID: 15575171
[TBL] [Abstract][Full Text] [Related]
7. Risedronate versus alendronate in older patients with osteoporosis at high risk of fracture: an Italian cost-effectiveness analysis.
Berto P; Maggi S; Noale M; Lopatriello S
Aging Clin Exp Res; 2010 Apr; 22(2):179-88. PubMed ID: 20145427
[TBL] [Abstract][Full Text] [Related]
8. A systematic review and economic evaluation of alendronate, etidronate, risedronate, raloxifene and teriparatide for the prevention and treatment of postmenopausal osteoporosis.
Stevenson M; Jones ML; De Nigris E; Brewer N; Davis S; Oakley J
Health Technol Assess; 2005 Jun; 9(22):1-160. PubMed ID: 15929857
[TBL] [Abstract][Full Text] [Related]
9. Comparison of risedronate to alendronate and calcitonin for early reduction of nonvertebral fracture risk: results from a managed care administrative claims database.
Watts NB; Worley K; Solis A; Doyle J; Sheer R
J Manag Care Pharm; 2004; 10(2):142-51. PubMed ID: 15032563
[TBL] [Abstract][Full Text] [Related]
10. Impact of noncompliance with alendronate and risedronate on the incidence of nonvertebral osteoporotic fractures in elderly women.
Blouin J; Dragomir A; Moride Y; Ste-Marie LG; Fernandes JC; Perreault S
Br J Clin Pharmacol; 2008 Jul; 66(1):117-27. PubMed ID: 18460036
[TBL] [Abstract][Full Text] [Related]
11. Efficacy and safety of alendronate and risedronate for postmenopausal osteoporosis.
Iwamoto J; Takeda T; Sato Y
Curr Med Res Opin; 2006 May; 22(5):919-28. PubMed ID: 16709313
[TBL] [Abstract][Full Text] [Related]
12. RisedronatE and ALendronate Intervention over Three Years (REALITY): minimal differences in fracture risk reduction.
Curtis JR; Westfall AO; Cheng H; Saag KG; Delzell E
Osteoporos Int; 2009 Jun; 20(6):973-8. PubMed ID: 18946630
[TBL] [Abstract][Full Text] [Related]
13. Hip fractures in users of first- vs. second-generation bisphosphonates.
Mamdani M; Kopp A; Hawker G
Osteoporos Int; 2007 Dec; 18(12):1595-600. PubMed ID: 17767369
[TBL] [Abstract][Full Text] [Related]
14. Risedronate prevents hip fractures, but who should get therapy?
Deal CL
Cleve Clin J Med; 2002 Dec; 69(12):964, 968-70, 973-6. PubMed ID: 12546269
[TBL] [Abstract][Full Text] [Related]
15. Greater first year effectiveness drives favorable cost-effectiveness of brand risedronate versus generic or brand alendronate: modeled Canadian analysis.
Grima DT; Papaioannou A; Thompson MF; Pasquale MK; Adachi JD
Osteoporos Int; 2008 May; 19(5):687-97. PubMed ID: 18008100
[TBL] [Abstract][Full Text] [Related]
16. Fracture risk in women with osteoporosis initiated on gastro-resistant risedronate versus immediate release risedronate or alendronate: a claims data analysis in the USA.
Eisman JA; Cortet B; Boolell M; Ionescu-Ittu R; Vekeman F; Heroux J; Thomasius F
Osteoporos Int; 2023 May; 34(5):977-991. PubMed ID: 36872338
[TBL] [Abstract][Full Text] [Related]
17. Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group.
Harris ST; Watts NB; Genant HK; McKeever CD; Hangartner T; Keller M; Chesnut CH; Brown J; Eriksen EF; Hoseyni MS; Axelrod DW; Miller PD
JAMA; 1999 Oct; 282(14):1344-52. PubMed ID: 10527181
[TBL] [Abstract][Full Text] [Related]
18. Therapies for treatment of osteoporosis in US women: cost-effectiveness and budget impact considerations.
Tosteson AN; Burge RT; Marshall DA; Lindsay R
Am J Manag Care; 2008 Sep; 14(9):605-15. PubMed ID: 18778176
[TBL] [Abstract][Full Text] [Related]
19. Aging bone and osteoporosis: strategies for preventing fractures in the elderly.
Ettinger MP
Arch Intern Med; 2003 Oct; 163(18):2237-46. PubMed ID: 14557222
[TBL] [Abstract][Full Text] [Related]
20. Denosumab compared with risedronate in postmenopausal women suboptimally adherent to alendronate therapy: efficacy and safety results from a randomized open-label study.
Roux C; Hofbauer LC; Ho PR; Wark JD; Zillikens MC; Fahrleitner-Pammer A; Hawkins F; Micaelo M; Minisola S; Papaioannou N; Stone M; Ferreira I; Siddhanti S; Wagman RB; Brown JP
Bone; 2014 Jan; 58():48-54. PubMed ID: 24141036
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]